enGene Therapeutics Warrants
ENGNW
16 hedge funds and large institutions have $6.54M invested in enGene Therapeutics Warrants in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 16 → 16 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
12.6% less ownership
Funds ownership: 23.72% → 11.12% (-13%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
77% less capital invested
Capital invested by funds: $28.6M → $6.54M (-$22.1M)
83% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$49.6K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$38.9K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$640 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOCH
Blue Owl Capital Holdings
New York
|
-$1.47M |
| 2 |
ACM
Atalaya Capital Management
New York
|
-$347K |
| 3 |
CAC
Cowen and Company
New York
|
-$182K |
| 4 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$126K |
| 5 |
TCM
Tenor Capital Management
New York
|
-$31.2K |
ENGNW Hedge Fund Activity: Q2 2024 in Review
16 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics Warrants (ENGNW) for Q2 2024, worth a combined $6.54M — down 77% from $28.6M a quarter earlier.
Fund positioning in ENGNW was balanced in Q2 2024: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 6 trimmed.
The largest buyer was Wolverine Asset Management, adding an estimated $49.6K. The largest seller was Blue Owl Capital Holdings, cutting an estimated $1.47M.
- 16 institutional investors held enGene Therapeutics Warrants (ENGNW) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $6.54M of enGene Therapeutics Warrants stock for Q2 2024, down 77% quarter-over-quarter.
- 2 funds opened new enGene Therapeutics Warrants positions in Q2 2024 and 2 closed out, a net change of 0 holders.
- The largest enGene Therapeutics Warrants buyer in Q2 2024 was Wolverine Asset Management, an estimated $49.6K added.
- The largest enGene Therapeutics Warrants seller in Q2 2024 was Blue Owl Capital Holdings, an estimated $1.47M sold.
Based on aggregated 13F filings for Q2 2024.